Mirtazapin !@ctavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin !@ctavis, is a NaSSA presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin !@ctavis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used within the antidepressant therapeutic class to manage depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depressive episodes in major depressive disorder: helps restore sleep and appetite. - Treatment‑resistant major depressive disorder: may be considered when other antidepressants have not achieved adequate response.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents

Mirtazapine requires careful monitoring in several clinical situations. - Assess hepatic function: adjust use in severe liver impairment. - Monitor weight: potential for significant weight gain. - Evaluate for suicidal ideation: particularly during the initial treatment phase. - Avoid abrupt discontinuation: taper dosage to reduce withdrawal symptoms. - Use caution in elderly patients: increased risk of sedation and falls. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with a variety of medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome. - Strong CYP2D6 inhibitors: may raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Antihistamines: increased drowsiness. - Carbamazepine or other enzyme inducers: may reduce efficacy of mirtazapine.